Resultaten visas 1 - 10 / 17
resultat / per sida
Vilka publikationsuppgifter finns i tjänsten?
Publikationens namn
Upphovspersoner
Publikationskanal
År
Publicationer information ikon

Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine

Referentgranskad
Öppen tillgång
DOI
10.3402/ecrj.v2.26385
Myllarniemi, Marjukka; Kaarteenaho, Riitta
European Clinical Respiratory Journal2015Publicationer information ikon

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Referentgranskad
DOI
10.1056/NEJMoa1903076
SENSCIS Trial Investigators; Distler, Oliver; Highland, Kristin B.; Gahlemann, Martina; Azuma, Arata...
The new england journal of medicine2019Publicationer information ikon

Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

Referentgranskad
Öppen tillgång
DOI
10.1111/resp.14116
Durheim, Michael T.; Bendstrup, Elisabeth; Carlson, Lisa; Sutinen, Eva M.; Hyldgaard, Charlotte; Kal...
Respirology2021Publicationer information ikon

Nintedanib in Idiopathic Pulmonary Fibrosis:Practical Management Recommendations for Potential Adverse Events

Referentgranskad
DOI
10.1159/000495046
Bendstrup, E.; Wuyts , W.; Alfaro, T.; Chaudhuri , N.; Cornelissen , R.; Kreuter , M.; Melgaard Niel...
Anticancer research2019Publicationer information ikon

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Referentgranskad
Öppen tillgång
DOI
10.1186/s12931-016-0328-5
Lehtonen, Siri T.; Veijola, Anniina; Karvonen, Henna; Lappi-Blanco, Elisa; Sormunen, Raija; Korpela,...
Respiratory research2016Publicationer information ikon

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Referentgranskad
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarte...
Respiratory Research (online]2016Publicationer information ikon

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Referentgranskad
Öppen tillgång
Lehtonen Siri T, Veijola Anniina, Karvonen Henna, Lappi-Blanco Elisa, Sormunen Raija, Korpela Saara,...
RESPIRATORY RESEARCH (ONLINE]2016Publicationer information ikon

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Referentgranskad
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarte...
Respiratory Research2016Publicationer information ikon

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Referentgranskad
Öppen tillgång
DOI
10.1182/blood.2019004509
Toledo, MAS; Gatz, M; Sontag, S; Gleixner, KV; Eisenwort, G; Feldberg, K; Hamouda, AEI; Kluge, F; Gu...
Blood2021Publicationer information ikon

Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine

Referentgranskad
Myllärniemi M; Kaarteenaho R
European Clinical Respiratory Journal2015

Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine

Referentgranskad
Öppen tillgång
DOI
10.3402/ecrj.v2.26385
2015

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Referentgranskad
DOI
10.1056/NEJMoa1903076
2019

Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

Referentgranskad
Öppen tillgång
DOI
10.1111/resp.14116
2021

Nintedanib in Idiopathic Pulmonary Fibrosis:Practical Management Recommendations for Potential Adverse Events

Referentgranskad
DOI
10.1159/000495046
2019

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Referentgranskad
Öppen tillgång
DOI
10.1186/s12931-016-0328-5
2016

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Referentgranskad
2016

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Referentgranskad
Öppen tillgång
2016

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

Referentgranskad
2016

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Referentgranskad
Öppen tillgång
DOI
10.1182/blood.2019004509
2021

Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine

Referentgranskad
2015